Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's
Dr. Reddy's Laboratories warns that the proposed 200% US tariff on generic medicines will lead to higher costs for American consumers. The company's CEO stated that shifting manufacturing to the US is currently impractical due to cost differences.
Why it matters
It highlights the potential economic impact of protectionist trade policies on the affordability of essential healthcare products.
The US is putting generic medicines on the tariff map, with duties set to rise to as much as 200% in the coming years to boost local manufacturing. But will the cure soothe the pain for American consumers—or inflame it further? Dr Reddy's Laboratories said that higher import duties will likely push up medicine prices. Furthermore, despite the policy push, moving manufacturing to the country is impractical. Speaking during the company's earnings call on Wednesday, Dr Reddy's CEO Erez Israeli said any increase in tariffs would inevitably translate into higher prices for medicines in the US.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in